Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3

[1]  Hyunyoung Jeong,et al.  Isoform-Specific Regulation of Cytochromes P450 Expression by Estradiol and Progesterone , 2013, Drug Metabolism and Disposition.

[2]  C. Thangavel,et al.  Inherent sex‐dependent regulation of human hepatic CYP3A5 , 2013, British journal of pharmacology.

[3]  M. Mikov,et al.  Tacrolimus as a part of immunosuppressive treatment in kidney transplantation patients: sex differences. , 2012, Gender medicine.

[4]  Russ B Altman,et al.  PharmGKB summary: very important pharmacogene information for CYP3A5. , 2012, Pharmacogenetics and genomics.

[5]  D. Ferrante,et al.  The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation , 2012, European Journal of Clinical Pharmacology.

[6]  M. Makuuchi,et al.  Bottom‐up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power , 2011, Biopharmaceutics & drug disposition.

[7]  R. Altman,et al.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). , 2011, Pharmacogenetics and genomics.

[8]  Kazuhiko Yamamoto,et al.  Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial , 2011, Modern rheumatology.

[9]  L. Bertilsson,et al.  4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. , 2011, British journal of clinical pharmacology.

[10]  Wei-Hua Wu,et al.  Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism , 2010, European Journal of Clinical Pharmacology.

[11]  H. Hashimoto,et al.  Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study , 2009, Modern rheumatology.

[12]  D. Greenblatt,et al.  Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs , 2008, Journal of clinical pharmacology.

[13]  Zhi-Hong Liu,et al.  Successful treatment of class V+IV lupus nephritis with multitarget therapy. , 2008, Journal of the American Society of Nephrology : JASN.

[14]  J. Hou,et al.  Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients , 2008, Biopharmaceutics & drug disposition.

[15]  G. Drusano,et al.  Sex differences in CYP3A activity using intravenous and oral midazolam , 2006, Clinical pharmacology and therapeutics.

[16]  M. Hebert,et al.  EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO , 2006, Drug Metabolism and Disposition.

[17]  G. Anderson.  Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. , 2005, Journal of women's health.

[18]  D. Greenblatt,et al.  The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates , 2005, Clinical Pharmacokinetics.

[19]  Peter Neuhaus,et al.  Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.

[20]  Kun Tang,et al.  Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. , 2002, Pharmacogenetics.

[21]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[22]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[23]  Leslie Z. Benet,et al.  Gender Effects in Pharmacokinetics and Pharmacodynamics , 1995, Drugs.

[24]  Y. Tanigawara,et al.  Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.

[25]  K. Iwasaki.  Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. , 2007, Drug metabolism and pharmacokinetics.